EFFECT OF ERANDADI GHANAVATI OVER KAISHORA GUGGULU AFTER VIRECHAN IN THE PATIENTS OF VATARAKTA (CHRONIC GOUT)
Phase 2
- Conditions
- Health Condition 1: M109- Gout, unspecified
- Registration Number
- CTRI/2024/08/072119
- Lead Sponsor
- All India Institute of Ayurveda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients presenting with the clinical features of Vatarakta (sandhi shotha(swelling), sandhi shola(pain), sparsh asahatvam (tenderness), twak vaivarnya(discolouration of skin), raga(redness), vidaha(burning sensation), stabdhata(stiffness))
2.Patients either sex between age group of 21-60 yrs.
3.Patients showing the Serum uric acid level 7 -10mg/dl.
Exclusion Criteria
1.Uncontrolled Diabetes and uncontrolled HTN
2.Subjects pre-diagnosed with autoimmune and infective disease of joints. E.g. tuberculous arthritis
3.Malignancy
4.Genetic Disorder e.g. Duchene muscular dystrophy
5.Pregnant and lactating women
6.History of hypersensitivity to any of the trial drug ingredient.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method •Improvement in the signs & symptoms (sandhi shotha(swelling)sandhi shola(pain), sparsh asahatvam (tenderness), twak vaivarnya(discolouration of skin), raga(redness), vidaha(burning sensation), stabdhata(stiffness)) of Vatarakta (Chronic Gout).Timepoint: BASELINE <br/ ><br>AFTER 6 WEEKS <br/ ><br>AFTER 12 WEEKS
- Secondary Outcome Measures
Name Time Method Reduction in the level of serum uric acid in the patients having Vatarakta (Chronic Gout). (approx 25% improvement is expected) <br/ ><br> <br/ ><br>Improvement in the quality of life of the patient.Timepoint: BASELINE <br/ ><br>AFTER 6 WEEKS <br/ ><br>AFTER 12 WEEKS